Quest Diagnostics Inc (DGX) FinancialsDGXQuest Diagnostics Inc

Quest Diagnostics Inc (DGX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diagnostic Information Services Business, accounting for 97.8% of total sales, equivalent to $2.83B. Another important revenue stream is All other operating segments. Understanding this composition is critical for investors evaluating how DGX navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Quest Diagnostics Inc maintains a gross margin of 32.53%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 15.18%, while the net margin is 10.98%. These profitability ratios, combined with a Return on Equity (ROE) of 14.35%, provide a clear picture of how effectively DGX converts its operational activities into shareholder value.

In the context of the broader market, DGX competes directly with industry leaders such as ASTH and NRC. With a market capitalization of $25.44B, it holds a leading position in the sector. When comparing efficiency, DGX's gross margin of 32.53% stands against ASTH's 9.10% and NRC's 56.41%. Such benchmarking helps identify whether Quest Diagnostics Inc is trading at a premium or discount relative to its financial performance.

Quest Diagnostics has shown strong revenue growth, with Q2 2026 revenue at $3.043 billion, up from $2.761 billion in Q2 2025. The gross margin is stable at around 32.53%, and the net income for Q2 2026 was $319 million, indicating solid profitability. The forward P/E ratio is 19.53, suggesting reasonable valuation relative to growth expectations.